Carlecortemcel-L

N/A

Report date: 2023/01/12 15:51:51

Base Information

Drug NameCarlecortemcel-L

Drug Alias NameHaematopoetic stem cell therapy - Teva/Gamida-CellStemEx

ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTeva Pharmaceutical Industries Ltd Loyola University Chicago

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesLoyola University Chicago Teva Pharmaceutical Industries Ltd

Active IndicationsN/A

Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A